TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Stanford University
Stanford University
Alliance for Clinical Trials in Oncology
Masonic Cancer Center, University of Minnesota
Northwestern University